Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Indivior PLC : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 09:15am EST

The company will report its earnings for FY 2018 on 02/14/2019. Generally, the company reports earnings in line with the consensus. In recent months, the 4 analysts from Thomson Reuters consensus have revised their EPS estimates downward.

Annual earnings per share is expected at 0.35 USD for 2018 (+ 342.9% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million $
Released
Forecast
Spread
1 014
1 008
0,61%
1 058
1 066
-0,76%
1 093
1 104
-1,0%

998

559
Operating income (EBITDA)
Million $
Released
Forecast
Spread
417
401
4,0%
401
410
-2,3%
416
429
-3,0%

339

31,7
Operating profit (EBIT)
Million $
Released
Forecast
Spread
377
377
-0,11%
387
368
5,0%
403
412
-2,1%

321

24,9
Pre-Tax Profit (EBT)
Million $
Released
Forecast
Spread
285
309
-7,6%
98,0
147
-33%
137
351
-61%

286

21,9
Net income
Million $
Released
Forecast
Spread
228
225
1,4%
35,0
60,3
-42%
58,0
260
-78%

253

32,4
EPS
 $
Released
Forecast
Spread
0,31
0,31
-0,32%
0,05
0,15
-66%
0,08
0,35
-77%

0,35

-0,03
Announcement Date02/18/201602/22/201702/15/2018

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INDIVIOR
01:12aINDIVIOR : Pharma firm Indivior launches generic version of own drug to beat cop..
AQ
02/20INDIVIOR : Launches Generic Version of Suboxone in US to Pre-empt Rivals
DJ
02/19INDIVIOR : Sandoz Launches New Generic to Treat Opioid Dependence
DJ
02/19LONDON STOCK EXCHANGE : HSBC, stronger pound pressure FTSE 100; Greggs outshines..
RE
02/15INDIVIOR : boosts profits, but warns of rising competition in America
AQ
02/14LONDON STOCK EXCHANGE : FTSE 100 squeezes out gains; ConvaTec drags midcaps
RE
02/14INDIVIOR : Costs cuts help Indivior post 2018 profit jump
RE
02/12INDIVIOR : Court Denies Emergency Motion to Block Dr. Reddy's Generic Medicine L..
DJ
02/12INDIVIOR : loses U.S. district court battle, copycat launches imminent
RE
02/11INDIVIOR PLC : annual earnings release
More news
Financials ($)
Sales 2019 562 M
EBIT 2019 30,4 M
Net income 2019 32,4 M
Finance 2019 115 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 13,09
EV / Sales 2019 1,58x
EV / Sales 2020 1,46x
Capitalization 1 003 M
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 2,75 $
Spread / Average Target 100%
EPS Revisions
Managers
NameTitle
Shaun Thaxter Chief Executive Officer & Executive Director
Howard H. Pien Chairman
Mark Crossley Chief Financial Officer & Executive Director
Christian Heidbreder Chief Scientific Officer
Ingo Elfering Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR-6.23%1 003
ABBVIE-13.23%120 322
MERCK KGAA7.89%14 216
KYOWA HAKKO KIRIN CO LTD5.82%10 456
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD18.98%9 280
JAZZ PHARMACEUTICALS PLC1.59%7 648